書誌事項
- タイトル別名
-
- Comparison between adverse events of half-dose and standard dose administration of sorafenib for advanced hepatocellular carcinoma
- シンコウ カン サイボウガン チリョウ ニ オケル Sorafenib ノ ユウガイ ジショウ ゲンリョウ カイシレイ ト スイショウ ヨウリョウ カイシレイ ノ ヒカク
この論文をさがす
抄録
We compared with the adverse events of half-dose (400 mg per day, n=13) administration and standard-dose (800 mg per day, n=12) administration of sorafenib as initial-dose treatment for advanced hepatocellular carcinoma. Baseline characteristics such as sex, age, Child Pugh's classification, and presence or absence of portal vein thrombosis and extrahepatic metastasis did not differ significantly between the two initial-dose groups. The dose of sorafenib was reduced because of adverse events in 75% of the standard-dose cases and in 38% the half-dose cases. The difference between the two groups in time to radiographic progression was not significant. A randomized, double-blind, study may be necessary to find the optimal dose of sorafenib for treatment of Japanese patients with advanced hepatocellular carcinoma lesions.<br>
収録刊行物
-
- 肝臓
-
肝臓 51 (7), 400-402, 2010
一般社団法人 日本肝臓学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390001204795058688
-
- NII論文ID
- 10026515353
-
- NII書誌ID
- AN00047770
-
- ISSN
- 18813593
- 04514203
-
- NDL書誌ID
- 10766275
-
- 本文言語コード
- ja
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可